SEPTInvestingStart Free

CERO 424B3: Secondary offering

Cero Therapeutics Holdings, Inc.

Filed with the SEC on · accession 0001213900-26-090061

CERO filed a 424B3 (prospectus (offering)) with the SEC on Aug 14, 2026. The final terms of an offering of shares or bonds.

Summary of the filing

Cero Therapeutics Holdings, Inc. filed a prospectus supplement to register 729,596,950 shares of common stock for sale, updating the prospectus with its quarterly report for the period ended June 30, 2026.

For details, click here →How to read a 424B3 →

Key details

shares offered$729.6M
IssuerCero Therapeutics Holdings, Inc.

✦ Ask GOAX AI about this filing — what it means for CERO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CERO?

Click here

Frequently asked questions

What did CERO file with the SEC on Aug 14, 2026?

CERO filed a 424B3 (Secondary offering). Cero Therapeutics Holdings, Inc. filed a prospectus supplement to register 729,596,950 shares of common stock for sale, updating the prospectus with its quarterly report for the period ended June 30, 2026.

What does a secondary offering mean for CERO stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

Other CERO SEC filings

Get alerts when CERO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
CERO overviewCERO analysisCERO newsLatest SEC filings